We read with interest the report of the randomized double-blind controlled trial by Fernández-Serrano and colleagues [1] suggesting that the administration of methyl-prednisolone (MPDN) with ceftriaxone plus levofl oxacin improves clinical variables in communityacquired pneumonia (CAP). Compared with randomly controlled studies in which patients benefi ted from corticosteroid treatment [2] [3] [4] , all patients of this study received the same antibiotics. It is striking that this study has overcome the problem that choice and dose of antibiotics may infl uence results.
cortico steroid treatment lacks effi cacy in cases of mild to moderate CAP [3] . Although additional subgroup analysis may lead to similar results to those of our study because more than 50% of patients in both studies had a pneumonia severity index [5] rating of IV or V [1, 3] , the target population for corticosteroid treatment should be precisely identifi ed. Moreover, although the authors administrated 620 mg MPDN per patient, we [3] and Meijvis and colleagues [4] showed a benefi cial eff ect with lower doses of corticosteroids over shorter periods. Th e authors should consider lower doses and shorter periods of MPDN treatment in a future study.
Although this study could clearly provide signifi cantly benefi cial evidence of the value of MPDN treatment, the severity of pneumonia should be addressed because of the potential risk associated with corticosteroid treatment. 
L E T T E R Authors' response
Jordi Dorca, Silvia Fernández-Serrano and Frederic Manresa
We thank Dr Suzuki and colleagues for their comments. Our study [1] aimed to demonstrate the potential eff ect of corticosteroid adjunctive therapy on the clinical outcome of severe CAP, so inclusion criteria included extensive radiological consolidation completely aff ecting at least two lobes, as well as a oxygen partial pressure/ inspired oxygen fraction ratio (pO 2 /FiO 2 ) <300. Th is is how we concluded that adjunctive MPDN improves respiratory failure and accelerates the timing of clinical resolution of severe CAP. In our opinion, only this population could benefi t from steroid administration.
We elected to give higher doses of corticosteroids than in other studies [3, 4, 6] to increase the chance of showing a positive eff ect. However, we cannot exclude that a lower dosage may have a benefi cial eff ect. Having said that, it is also possible that the improvement may be dosedependent; therefore, once evidence of a benefi t has been defi nitively shown in larger series, prospective controlled studies comparing diff erent doses and schedules will be needed.
